Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00319956 · ClinicalTrials.gov registry record · Phase 2

Trial II of Lung Protection With Azithromycin in the Preterm Infant

A Phase 2 study of Bronchopulmonary Dysplasia, sponsored by Hubert Ballard.

Completed
Registry status
Phase 2
Development phase
220
Enrollment target
1
Study location

NCT00319956: Completed Phase 2 study of Bronchopulmonary Dysplasia, sponsored by Hubert Ballard.

NCT00319956 is a Phase 2 study of Bronchopulmonary Dysplasia that has completed, run by Hubert Ballard. The registered enrollment target is 220 participants, roughly in line with the 229-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00319956, a Phase 2 study of Bronchopulmonary Dysplasia, has completed, sponsored by Hubert Ballard.

COMPLETED
Registry status
Phase 2
Development phase
220 participants
Enrollment target
1
Study location

Study Summary

The hypothesis of this study is that administration of azithromycin to ventilated premature infants will decrease the incidence and severity of BPD. The purpose of this study is to determine if Azithromycin treatment is beneficial for prevention of bronchopulmonary dysplasia in preterm infants.

Primary Outcome

comparison of the % Incidence of bronchopulmonary dysplasia (BPD) for the azithromycin vs placebo groups.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Azithromycin

Study Locations (1)

Kentucky

  • University of Kentucky Medical Center - Lexington

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2004-09
Est. Completion 2012-06
Phase Phase 2
Hubert Ballard

1 total trials

What the finished NCT00319956 record still lists

NCT00319956 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 229-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target.

The record links to 1 condition, with Bronchopulmonary Dysplasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00319956 reports a single indexed study location in Kentucky.

Frequently Asked Questions

What is clinical trial NCT00319956 about?

NCT00319956 is a clinical study titled "Trial II of Lung Protection With Azithromycin in the Preterm Infant". The hypothesis of this study is that administration of azithromycin to ventilated premature infants will decrease the incidence and severity of BPD. The purpose of this study is to determine if Azithromycin treatment is beneficial for prevention of bronchopulmonary dysplasia in preterm infants.

What is the current status of trial NCT00319956?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2004-09. Estimated completion is 2012-06.

What conditions does trial NCT00319956 study?

This clinical trial studies the following conditions: Bronchopulmonary Dysplasia.

What interventions are being tested in trial NCT00319956?

The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).

Who is sponsoring clinical trial NCT00319956?

This trial is sponsored by Hubert Ballard, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00319956 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bronchopulmonary Dysplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00319956's enrollment target sits among peer trials

220 12th of 29 higher than 18 of 29 other Bronchopulmonary Dysplasia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bronchopulmonary Dysplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00319956, the US trial registry maintained by the National Library of Medicine. NCT00319956 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.